Abstract: The invention is a cosmetic or dermatological formulation comprising a) at least one polyol in a concentration of from 0.1 to 20% by weight, based on the total weight of the formulation, and b) at least one diol selected from the group consisting of 2-methyl-1,3-propanediol, pentanediol, and hexanediol, in a concentration of from 0.1 to 25% by weight, based on the total weight of the formulation. The invention also includes formulations further comprising at least one antioxidant, and formulations further comprising at least one UV filter. The invention also includes a method of moisturizing skin comprising applying the formulation to the skin. The invention further includes a method for reducing the tacky sensation, a method for reducing the viscosity, and a method for increasing the stability of a polyol-containing formulation comprising adding a diol selected from the group consisting of 2-methyl-1,3-propanediol, pentanediol, and hexanediol.
Type:
Grant
Filed:
August 25, 2006
Date of Patent:
July 15, 2014
Assignee:
Beiersdorf AG
Inventors:
Rainer Kröpke, Jens Nielsen, Kathrin Wolter
Abstract: There is provided compounds of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
Type:
Grant
Filed:
April 16, 2010
Date of Patent:
July 15, 2014
Assignee:
Centro Nacional de Investigaciones Oncologicas (CNIO)
Inventors:
Joaquin Pastor Fernández, Sonia Martínez Gonzalez, Julen Oyarzabal Santamarina
Abstract: The present invention provides compositions and formulations of compounds having formula (I) and pharmaceutically acceptable derivatives thereof, wherein p, R1, R2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease.
Type:
Grant
Filed:
July 9, 2009
Date of Patent:
July 8, 2014
Assignee:
Anigion Biomedica Corp.
Inventors:
Weizhong Cai, Prakash Narayan, Bijoy Panicker, David E. Smith
Abstract: There has been a need for coelenterazine analogs that exhibit luminescence properties different from those of known coelenterazine analogs. The present invention provides the compound represented by general formula (1).
Type:
Grant
Filed:
August 22, 2013
Date of Patent:
July 1, 2014
Assignees:
JNC Corporation, Tokyo Institute of Technology
Abstract: The present invention relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of MMP inhibiting compounds that exhibit increased potency, metabolic stability and/or reduced toxicity in relation to currently known MMP inhibitors for the treatment of pain and other diseases such as cancer. Additionally, the present invention relates to methods for treating pain in a patient comprising administering to the patient a pain-reducing effective amount of a present compound.
Abstract: A deodorizing composition containing: (a) from about 10 to 30% by weight of a dialkyl carbonate corresponding to formula I: wherein R1 is a linear alkyl and/or alkenyl group containing from about 6 to 22 carbon atoms, a 2-ethylhexyl, an isotridecyl, an isostearyl group or a group derived from a polyol containing 2 to 15 carbon atoms and at least two hydroxyl groups; R2 has the same meaning as R1 or is an alkyl group containing from about 1 to 5 carbon atoms; and n and m, independently of one another, represent a number up to 100, and (b) an antiperspirant.
Type:
Grant
Filed:
September 2, 2008
Date of Patent:
July 1, 2014
Assignee:
Cognis IP Management GmbH
Inventors:
Stefan Bruening, Helga Gondek, Achim Ansmann
Abstract: The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, this invention relates to compositions and methods for selectively enhancing fungal sensitivity to antifungal compounds.
Type:
Grant
Filed:
December 19, 2006
Date of Patent:
June 24, 2014
Assignee:
MethylGene Inc.
Inventors:
Nafsika Georgopapadakou, Wenqi Hu, Nadia Campeol, Jean Bedard, Robert Deziel, Alain Ajamian
Abstract: The invention discloses a stable intravenous Propofol oil-in-water emulsion composition having mixed preservatives of low toxicity that is capable of withstanding accidental contamination of bacteria and fungi. The preservative system employed comprising of monoglyceryl ester of lauric acid (Monolaurin) and a member selected from (a) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin); (b) edetate; and (c) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin) and edetate.
Abstract: A method of inhibiting the inflammatory process, the method comprising administering to a mammal suffering from inflammation a therapeutically effective amount of a pharmaceutical composition comprising a compound where: R is a C1-C10 alkylene group, in which, when the number of carbon atoms is at least 2, there are optionally 1 or 2 non-adjacent double bonds; 1 to 3 non-adjacent methylene groups are optionally replaced by NR1 (where R1 is H, alkyl, or acyl), O, or S; and 1 or 2 methylene groups are optionally replaced by a carbonyl or hydroxymethylene group and pharmaceutically acceptable esters or salts of the compounds and wherein the inflammatory process results from a disease selected from the group consisting of ulcerative colitis, endotoxic shock, rheumatoid arthritis, juvenile arthritis, osteoarthritis, psoriasis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, insulin dependent diabetes mellitus, gout, psoriatic arthritis, reactive arthritis, vital or post-viral arthritis and an
Type:
Grant
Filed:
October 7, 2011
Date of Patent:
June 17, 2014
Assignee:
ProteoTech, Inc.
Inventors:
Virginia Sanders, Joel Cummings, Alan D Snow
Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
Type:
Grant
Filed:
May 2, 2011
Date of Patent:
June 17, 2014
Assignee:
Cephalon, Inc.
Inventors:
Jonathan D. Eichman, John Hontz, Rajendra K. Khankari, Sathasivan Indiran Pather, Joseph R. Robinson
Abstract: The present invention relates to a purine compound useful as a kinase inhibitor. The compound has the structure (I) or a pharmaceutically acceptable salt thereof.
Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein Y, R1, R2, R3, R4, RA, and RB are defined herein.
Abstract: The present disclosure provides a method of increasing an immune response in an individual, the method involving administering to an individual in need thereof an inhibitor of SIRT1. The present disclosure provides a method of reducing an immune response, e.g., to treat chronic immune hyperactivity, the method generally involving administering to an individual in need thereof an activator of SIRT1. The present disclosure provides a method of modulating activation and differentiation of CD4+ T cells.
Type:
Grant
Filed:
July 16, 2010
Date of Patent:
June 10, 2014
Assignee:
The J. David Gladstone Institutes
Inventors:
Eric M. Verdin, Melanie Ott, Hye-Sook Kwon, Hyungwook Lim
Abstract: The invention relates to an aqueous pharmaceutical composition, preferably an infusion solution, for parenteral administration which contains paracetamol and has an electrical conductivity of not more than 200 ?S cm?1.
Type:
Grant
Filed:
April 19, 2010
Date of Patent:
June 3, 2014
Assignee:
Fresenius Kabi Deutschland GmbH
Inventors:
David Dasberg, Georg Achleitner, Christiane Aichholzer
Abstract: The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.
Type:
Grant
Filed:
March 18, 2013
Date of Patent:
June 3, 2014
Assignees:
Shangong Luye Pharmaceutical Co., Ltd.
Inventors:
Youxin Li, Wanhui Liu, Yang Lv, Guanhua Du, Qingguo Meng, Mina Yang, Fengmei Zhou, Ju Li, Xuemei Zhang
Abstract: The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of central nervous system disorders.
Type:
Grant
Filed:
May 24, 2012
Date of Patent:
June 3, 2014
Assignee:
Allergan, Inc.
Inventors:
Alan C. Foster, Yong-Xin Li, Ursula Staubli, Veena Viswanath, Lauren Luhrs
Abstract: The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.
Type:
Grant
Filed:
November 2, 2012
Date of Patent:
June 3, 2014
Assignee:
Nuvo Research Inc.
Inventors:
Jagat Singh, Joseph Zev Shainhouse, Bradley S. Galer, Robert Dominic King-Smith, Lisa Marie Grierson, Maria Burian, Jonathan Wilkin, Edward Kisak, John M. Newsam
Abstract: The present invention relates to methods of administering compositions comprising a progesterone receptor antagonist for use in treating estrogen-dependent conditions. The invention is also directed to methods for treating pain associated with endometriosis. The compositions may be administered to females with endometriosis as well as to females undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. In certain embodiments, the invention provides a method for suppressing endometrial proliferation.